Cerus Corporation announced that it will release its third quarter 2026 financial results on Monday, November 2, 2026, after the close of the stock market.

The company plans to host a conference call and webcast at 4:30 pm ET on the same day. During this session, management will discuss the financial results and provide a general business overview and outlook.

Webcast and Replay Details

Investors can access the live webcast and presentation slides via the Investor Relations page of the Cerus website. Participants are encouraged to join the call 10 minutes prior to the start of the event. A replay of the call will be available on the company’s website approximately three hours after the live event concludes and will remain accessible through November 23, 2026.

Company Profile

Cerus Corporation is dedicated to safeguarding the world’s blood supply. Headquartered in Concord, California, the company develops and supplies pathogen-protected blood components to blood centers and hospitals.

Key product statuses include:

• INTERCEPT Blood System: Available globally for platelets and plasma; holds both CE mark and FDA approval.
• INTERCEPT Fibrinogen Complex: Approved in the U.S. for treating bleeding associated with fibrinogen deficiency.
• INTERCEPT Red Blood Cell System: Under regulatory review in Europe and in late-stage clinical development in the U.S.

Cerus Corporation raised its full-year 2026 sales guidance to a range of $229.000 million to $231.000 million, up from the previous estimate of $227.000 million to $231.000 million, following a second-quarter report where earnings per share met analyst expectations. The guidance increase signals management’s confidence in sustained demand for its INTERCEPT Fibrinogen Complex (IFC) franchise, despite the company’s Q2 sales of $57.441 million missing the consensus estimate of $60.933 million by 5.73%. This upward revision contrasts with the broader market expectation of $245.200 million for the full year, highlighting a cautious but improving outlook amidst macroeconomic headwinds.

The Q2 results, covering the period ended June 30, 2026, showed a net loss attributable to Cerus of $2.9 million, or $(0.01) per share, matching analyst consensus. This represents a significant improvement from the $(0.03) per share loss recorded in the same quarter last year. While top-line performance fell short of immediate quarterly expectations, the divergence between the EPS meet and sales miss underscores effective cost discipline. Total revenue rose 5% year-over-year to $63.3 million from $60.1 million, primarily driven by a 10% surge in product revenue to $57.4 million.

Financial Performance Highlights

Product gross profit increased slightly by 2% to $29.5 million, although the gross margin contracted to 51.4% from 55.2%. This margin compression was attributed to a weaker U.S. dollar relative to the Euro and higher inflationary product costs. Conversely, operating expenses declined 7% to $37.3 million from $40.1 million, largely due to reduced research and development (R&D) spending. R&D expenses dropped to $14.4 million from $18.9 million, reflecting the completion of the U.S. PMA submission for the INT200 device and lower development costs associated with government-funded projects.

What the Numbers Show

The strategic shift is evident in the balance between declining government contract revenue and robust product adoption. Government contract revenue fell 24% to $5.9 million from $7.7 million, a result of the completion of the FDA contract in 2025 and the wind-down of the BARDA 2016 contract. However, this decline was more than offset by U.S. IFC sales, which totaled $6.7 million, up from $5.6 million previously. The substantial improvement in non-GAAP adjusted EBITDA to $3.0 million from $0.9 million demonstrates that cost controls, particularly in R&D, are successfully offsetting margin pressures and narrowing the net loss.

Cerus also strengthened its financial position through debt refinancing. Cash, cash equivalents, and short-term investments stood at $56.3 million at June 30, 2026, down from $82.9 million at December 31, 2025. The company reduced its outstanding term loan by $30 million, funded by $20 million in cash and $10 million drawn from a new, lower-cost revolving credit facility. As of June 30, 2026, Cerus had $35.0 million outstanding on its term loan and $30.1 million drawn on its revolving credit facility, with an additional $14.9 million available depending on eligible assets.